2023
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
1994
NEOPLASMS OF THE BLADDER, PROSTATE, AND TESTIS
Heiken J, Forman H, Brown J. NEOPLASMS OF THE BLADDER, PROSTATE, AND TESTIS. Radiologic Clinics Of North America 1994, 32: 81-98. PMID: 8284363, DOI: 10.1016/s0033-8389(22)00339-6.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingProstate cancerResonance imagingProcedure of choiceTesticular cancerBladder cancerClinical trialsTransrectal ultrasonographyUrinary bladderTransurethral ultrasonographyComputed tomographyCancerBladderStagingJudicious useUltrasonographyProstateTomographyTestisImagingCarcinomaNeoplasmsTrials